AKBA · CIK 0001517022 · operating
Based in Cambridge, Massachusetts, Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease patients. The company's commercial product is Auryxia (ferric citrate), which treats hyperphosphatemia in dialysis-dependent chronic kidney disease patients and iron deficiency anemia in non-dialysis-dependent patients. The company's lead development program is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor currently in Phase III trials for anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis-dependent patient populations.
Akebia's pipeline also includes early-stage programs: AKB-9090 for cardiac surgery-related acute kidney injury and acute respiratory distress syndrome, and AKB-10108 for retinopathy of prematurity in neonates. The company has established a collaboration with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian markets, providing geographic diversification for its lead program.
The company operates with 181 full-time employees and is incorporated in Delaware with listing on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.02 | $-0.02 | +93.9% | |
| 2024 | $-0.33 | $-0.33 | -17.9% | |
| 2023 | $-0.28 | $-0.28 | +45.1% | |
| 2022 | $-0.51 | $-0.51 | +70.0% | |
| 2021 | $-1.70 | $-1.70 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | $0.31 | $0.33 | +24.0% | |
| 2017 | $0.25 | $0.26 | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001517022-26-000020 | SEC ↗ |
| 2024-12-31 | 2025-03-13 | 0001628280-25-012470 | SEC ↗ |
| 2023-12-31 | 2024-03-14 | 0001628280-24-011270 | SEC ↗ |
| 2022-12-31 | 2023-03-10 | 0001628280-23-007539 | SEC ↗ |
| 2021-12-31 | 2022-03-01 | 0001628280-22-004522 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0001628280-21-003283 | SEC ↗ |
| 2019-12-31 | 2020-03-12 | 0001564590-20-010491 | SEC ↗ |
| 2018-12-31 | 2019-03-26 | 0001564590-19-009340 | SEC ↗ |
| 2017-12-31 | 2018-03-12 | 0001564590-18-005286 | SEC ↗ |
| 2016-12-31 | 2017-03-06 | 0001564590-17-003466 | SEC ↗ |
| 2015-12-31 | 2016-03-14 | 0001564590-16-014700 | SEC ↗ |
| 2014-12-31 | 2015-03-04 | 0001564590-15-001260 | SEC ↗ |